{"id":954209,"date":"2026-04-23T08:40:16","date_gmt":"2026-04-23T12:40:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/"},"modified":"2026-04-23T08:40:16","modified_gmt":"2026-04-23T12:40:16","slug":"renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/","title":{"rendered":"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting"},"content":{"rendered":"

\nAccepted Abstract is a Sub-Study in RenovoRx\u2019s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP\u2122 Therapy Platform\u2019s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of Chemotherapy
\n<\/h2>\n
\n

MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc<\/strong><\/a>. (\u201cRenovoRx\u201d or \u201cthe Company\u201d) (Nasdaq: RNXT)<\/strong>, a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath<\/strong>\u00ae<\/strong><\/sup>, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub\u2011study of its ongoing Phase III TIGeR\u2011PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n

The abstract, entitled \u201cThe TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study<\/em><\/strong>,<\/em>\u201d<\/em><\/strong> explores RenovoRx\u2019s lead product candidate, intra-arterial delivery of gemcitabine via RenovoCath (known as IAG), and its potential to reduce systemic levels of the chemotherapy gemcitabine and increase levels of its inactive metabolite compared with intravenous gemcitabine. Additionally, the abstract studies IAG administration and its direct correlation between the metabolite levels and CA 19-9, a biomarker commonly used to assess potential chemotherapy response.<\/p>\n

\u201cThis study provides important insights into how targeted intra-arterial delivery of chemotherapy may optimize drug distribution and pharmacologic activity in locally advanced pancreatic cancer,\u201d said Dr. Ramtin Agah, RenovoRx\u2019s Executive Chairman and Chief Medical Officer, and study co-author. \u201cWe believe IAG has the potential to enhance effectiveness of therapeutic delivery while reducing systemic toxicity and common side effects.\u201d<\/p>\n

The 2026 ASCO Annual Meeting will be held May 29 \u2013 June 2, 2026, in Chicago, Illinois, with the online publication of the abstract scheduled for May 21, 2026, at 5:00 P.M. ET.<\/p>\n

\n Abstract Details:<\/strong>
\n
\n Online Publication Date & Time: <\/strong>May 21, 2026, at 5:00 P.M. ET
Number for Publication:<\/strong> E16463
Title: <\/strong>The TIGeR-PaC Phase III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study.\u00a0<\/p>\n

\n About RenovoRx, Inc.<\/strong>
\n
\n RenovoRx, Inc. (Nasdaq: RNXT)<\/strong>\u00a0is a life sciences company developing innovative targeted oncology therapies and commercializing\u00a0RenovoCath<\/strong>\u00ae<\/strong><\/sup>, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx\u2019s patented\u00a0Trans-Arterial Micro-Perfusion (TAMP\u2122)<\/strong>\u00a0therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy\u2019s toxicities versus systemic intravenous therapy. RenovoRx\u2019s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.<\/p>\n

RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In its first full year of commercial efforts, RenovoRx generated approximately $1.1 million in RenovoCath sales and learned valuable lessons that will help drive growth in 2026 and beyond. Several customers have already initiated repeat orders and the number of medical institutions initiating new RenovoCath orders is expanding, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.<\/p>\n

RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA\u2019s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company\u2019s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.<\/p>\n

The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.<\/p>\n

For more information, visit www.renovorx.com<\/a>. Follow RenovoRx on\u00a0Facebook<\/a>,\u00a0LinkedIn<\/a>, and\u00a0X<\/a>.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
This press release and statements of the Company\u2019s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated benefits to the Company of the clinical study abstract described herein, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as \u201cmay,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cforecasts,\u201d \u201cestimates,\u201d \u201cintends,\u201d and \u201cpotential,\u201d or the negative of these terms or other comparable terminology regarding RenovoRx\u2019s expectations, strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue-generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and\/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled \u201cRisk Factors\u201d in documents that we file from time to time with the Securities and Exchange Commission.<\/p>\n

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.<\/p>\n

\n Investor Contact<\/strong>:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@KCSA.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Accepted Abstract is a Sub-Study in RenovoRx\u2019s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP\u2122 Therapy Platform\u2019s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of Chemotherapy MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (\u201cRenovoRx\u201d or \u201cthe Company\u201d) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath\u00ae, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub\u2011study of its ongoing Phase III TIGeR\u2011PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, entitled \u201cThe TIGeR-PaC Phase 3 III Clinical … <\/p>\n

Continue reading “RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954209","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Accepted Abstract is a Sub-Study in RenovoRx\u2019s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP\u2122 Therapy Platform\u2019s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of Chemotherapy MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (\u201cRenovoRx\u201d or \u201cthe Company\u201d) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath\u00ae, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub\u2011study of its ongoing Phase III TIGeR\u2011PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, entitled \u201cThe TIGeR-PaC Phase 3 III Clinical … Continue reading "RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T12:40:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting\",\"datePublished\":\"2026-04-23T12:40:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/\"},\"wordCount\":1496,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/\",\"name\":\"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=\",\"datePublished\":\"2026-04-23T12:40:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Market Newsdesk","og_description":"Accepted Abstract is a Sub-Study in RenovoRx\u2019s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP\u2122 Therapy Platform\u2019s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of Chemotherapy MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (\u201cRenovoRx\u201d or \u201cthe Company\u201d) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath\u00ae, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub\u2011study of its ongoing Phase III TIGeR\u2011PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, entitled \u201cThe TIGeR-PaC Phase 3 III Clinical … Continue reading \"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-23T12:40:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting","datePublished":"2026-04-23T12:40:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/"},"wordCount":1496,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/","name":"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=","datePublished":"2026-04-23T12:40:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTQyOCM3NTUxNDM2IzIyMDkxNTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP\u2122 Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954209"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954209\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}